Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Other oral health

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 6 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Sucralfate suspension (topical) vs Placebo suspension

Duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in mean duration of episodes compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment
MD -1.00 [-5.69, 3.69]
1 study · 35 participants
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment (3 months)
MD -1.09 [-2.61, 0.43]
1 study · 30 participants
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment
MD 1.40 [-0.15, 2.95]
1 study · 35 participants
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment (3 months)
MD -0.38 [-0.87, 0.11]
1 study · 30 participants
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Number of painful days · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in number of painful days compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment
MD 9.00 [-4.25, 22.25]
1 study · 35 participants
GRADE not reported

Sucralfate suspension (topical) vs Placebo suspension

Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Sucralfate suspension (topical) showed no clear difference in frequency of oral ulcers compared with placebo suspension; GRADE not reported.

1 finding from 1 review

Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
End of treatment (3 months)
MD -0.80 [-2.12, 0.52]
1 study · 30 participants
GRADE not reported